JP2020531523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531523A5 JP2020531523A5 JP2020511307A JP2020511307A JP2020531523A5 JP 2020531523 A5 JP2020531523 A5 JP 2020531523A5 JP 2020511307 A JP2020511307 A JP 2020511307A JP 2020511307 A JP2020511307 A JP 2020511307A JP 2020531523 A5 JP2020531523 A5 JP 2020531523A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- period
- weeks
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550328P | 2017-08-25 | 2017-08-25 | |
| US62/550,328 | 2017-08-25 | ||
| PCT/US2018/047255 WO2019040453A1 (en) | 2017-08-25 | 2018-08-21 | HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531523A JP2020531523A (ja) | 2020-11-05 |
| JP2020531523A5 true JP2020531523A5 (enExample) | 2021-09-30 |
Family
ID=65436837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511307A Pending JP2020531523A (ja) | 2017-08-25 | 2018-08-21 | 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190062455A1 (enExample) |
| EP (1) | EP3672994A4 (enExample) |
| JP (1) | JP2020531523A (enExample) |
| KR (1) | KR20200037863A (enExample) |
| CN (1) | CN111278863A (enExample) |
| AU (1) | AU2018322032B2 (enExample) |
| BR (1) | BR112020003632A2 (enExample) |
| CA (1) | CA3072913A1 (enExample) |
| CL (1) | CL2020000397A1 (enExample) |
| IL (1) | IL272673B2 (enExample) |
| MA (1) | MA49960A (enExample) |
| MX (1) | MX2020002077A (enExample) |
| RU (1) | RU2020111574A (enExample) |
| TW (1) | TW201925224A (enExample) |
| WO (1) | WO2019040453A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114641270A (zh) * | 2019-11-15 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 防止水性蛋白质溶液中可见颗粒的形成 |
| TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| IL300245A (en) * | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
| EP4489782A4 (en) * | 2022-03-10 | 2026-03-25 | Omeros Corp | MASP-2 and MASP-3 inhibitors, and associated compositions and methods for the treatment of sickle cell disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| HUE049154T2 (hu) * | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| PT2861246T (pt) * | 2012-06-18 | 2021-04-05 | Univ Leicester | Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações |
| RS61351B1 (sr) * | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| CN117398458A (zh) * | 2015-11-09 | 2024-01-16 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2018
- 2018-08-21 MA MA049960A patent/MA49960A/fr unknown
- 2018-08-21 US US16/106,986 patent/US20190062455A1/en not_active Abandoned
- 2018-08-21 EP EP18847767.3A patent/EP3672994A4/en not_active Withdrawn
- 2018-08-21 BR BR112020003632-3A patent/BR112020003632A2/pt not_active Application Discontinuation
- 2018-08-21 RU RU2020111574A patent/RU2020111574A/ru unknown
- 2018-08-21 AU AU2018322032A patent/AU2018322032B2/en active Active
- 2018-08-21 CA CA3072913A patent/CA3072913A1/en active Pending
- 2018-08-21 JP JP2020511307A patent/JP2020531523A/ja active Pending
- 2018-08-21 WO PCT/US2018/047255 patent/WO2019040453A1/en not_active Ceased
- 2018-08-21 CN CN201880054825.8A patent/CN111278863A/zh active Pending
- 2018-08-21 MX MX2020002077A patent/MX2020002077A/es unknown
- 2018-08-21 IL IL272673A patent/IL272673B2/en unknown
- 2018-08-21 KR KR1020207008257A patent/KR20200037863A/ko not_active Ceased
- 2018-08-22 TW TW107129307A patent/TW201925224A/zh unknown
-
2020
- 2020-02-18 CL CL2020000397A patent/CL2020000397A1/es unknown
-
2023
- 2023-10-04 US US18/480,825 patent/US20240247078A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12544438B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| US20260139045A1 (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| JP4879884B2 (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| JP2022532927A5 (enExample) | ||
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| JP7551822B2 (ja) | 治療用抗体製剤 | |
| RU2013125775A (ru) | Способы лечения ревматоидного артрита с применением антагонистов il-17 | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2023527563A5 (enExample) | ||
| IL283424B2 (en) | Stabilized formulations that include antibodies against the interleukin receptor (il-4r) | |
| KR20150032941A (ko) | 약학 제제 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| US20210393777A1 (en) | Stable preparation comprising anti-pcsk9 antibody | |
| JP2023533963A5 (enExample) | ||
| RU2025100421A (ru) | Состав на основе антитела к компоненту c1s системы комплемента | |
| RU2024133531A (ru) | Стабильные высококонцентрированные составы на основе аргинина, содержащие антитело к pd-1, и способы их применения | |
| EA045866B1 (ru) | Состав терапевтического антитела | |
| HK40050174A (en) | Stable formulation containing anti-pcsk9 antibody | |
| NZ737043A (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| NZ737043B2 (en) | Treatment of beta-thalassemia using actrii ligand traps |